Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs

Current Pharmaceutical Design

Volumn 20, Issue 3, 2014, Pages 454-473

  Wang, Yancai ^a,b   Miao, Xiaoqing ^a   Sun, Lin ^a   Song, Ju ^a   Bi, Chao ^a   Yang, Xiao ^a   Zheng, Ying ^a  

^a University of Macau   (Macao)

^b Shandong Polytechnic University   (China)

Author keywords

Absorption; Drug targeting; Efficacy; Nanosuspensions; Pharmacokinetics; Toxicity; Transport

Indexed keywords

1,3 DICYCLOHEXYLUREA; 2 METHOXYESTRADIOL; AC 88; ALBENDAZOLE; BA 99; BAICALEIN; BUDESONIDE; CEFPODOXIME PROXETIL; CURCUMIN; CYCLOSPORIN A; ELND 006; ITRACONAZOLE; NITRENDIPINE; ORGANIC COMPOUND; ORIDONIN; PACLITAXEL; PUERARIN; REVAPRAZAN; SILIBININ; SPIRONOLACTONE; TOPOTECAN; UNCLASSIFIED DRUG; UREA;

ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CELL TRANSPORT; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TRANSPORT; HERBAL MEDICINE; HUMAN; IN VIVO STUDY; INTERNALIZATION; INTRAOCULAR DRUG ADMINISTRATION; NANOSUSPENSION FORMULATION; NEOPLASM; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY;

ANIMALS; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, BIOLOGICAL; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; SUSPENSIONS; WATER;

EID: 84894059960     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990403     Document Type: Review

References (141)

1. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm 2011; 409: 260-8.
2. Horii I. Regulatory science for the safety evaluation to risk assessment/management in non-clinical drug research and development. J Pharmacol Sci 2012; 118: 52-52.
3. Kakran M, Sahoo NG, Li L, et al. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. Int J Pharm 2010; 383: 285-92.
4. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3: 785-96.
5. Wang Y, Ma Y, Du Y, et al. Formulation and pharmacokinetics evaluation of puerarin nanocrystals for intravenous delivery. J Nanosci Nanotechnol 2012; 12: 6176-84.
6. Muller RH, Keck CM. Twenty years of drug nanocrystals: Where are we, and where do we go? Eur J Pharm Biopharm 2012; 80: 1-3.
7. Sharma P, Zujovic ZD, Bowmaker GA, et al. Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies. Int J Pharm 2011; 408: 138-51.
8. Mueller RH, Gohla S, Keck CM. State of the art of nanocrystals-Special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011; 78: 1-9.
9. Van Eerdenbrugh B, Van Den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
10. Duan C, Gao J, Zhang D, et al. Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin. Biomacromolecules 2011; 12: 4335-43.
11. Singare DS, Marella S, Gowthamrajan K, et al. Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm 2010; 402: 213-20.
12. Zhang W, Hughes J, Chen Y. Impacts of hematite nanoparticle exposure on biomechanical, adhesive, and surface electrical properties of Escherichia coli cells. Appl Environ Microbiol 2012; 78: 3905-15.
13. Gao L, Liu GY, Ma JL, et al. Drug nanocrystals: In vivo performances. J Control Release 2012; 160: 418-30.
14. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003; 18: 113-20.
15. Liversidge GG, Cundy KC. Particle-Size Reduction for Improvement of Oral Bioavailability of Hydrophobic Drugs. 1. Absolute Oral Bioavailability of Nanocrystalline Danazol in Beagle Dogs. Int J Pharm 1995; 125: 91-7.
16. Sunesen VH, Pedersen BL, Kristensen HG, Mullertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci 2005; 24: 305-13.
17. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004; 56: 827-40.
18. Gao YA, Qian SA, Zhang JJ. Physicochemical and Pharmacokinetic Characterization of a Spray-Dried Cefpodoxime Proxetil Nanosuspension. Chem Pharm Bull 2010; 58: 912-7.
19. Ghosh S, Chiang PC, Wahlstrom JL, et al. Oral delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol 2008; 102: 453-8.
20. Choi HY, Noh YH, Jin SJ, et al. Bioavailability and Tolerability of Combination Treatment With Revaprazan 200 mg + Itopride 150 mg: A Randomized Crossover Study in Healthy Male Korean Volunteers. Clin Ther 2012; 34: 1999-2010.
21. Wang Y, Li X, Wang L, et al. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomedicine 2011; 6: 1497-507.
22. Wang YC, Zhang DR, Liu ZP, et al. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 2010; 21: 155104.
23. Sun W, Mao S, Shi Y, Li LC, Fang L. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci 2011; 100: 3365-73.
24. Xia D, Cui F, Piao H, et al. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Pharm Res 2010; 27: 1965-76.
25. Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm 2011; 37: 243-51.
26. Sigfridsson K, Forssen S, Hollander P, Skantze U, De Verdier J. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm 2007; 67: 540-7.
27. Hopkins CR. ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another gamma-Secretase Inhibitor Fails in the Clinic. ACS Chem Neurosci 2011; 2: 279-80.
28. Quinn K, Gullapalli RP, Merisko-Liversidge E, et al. A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: Development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs. J Pharm Sci 2012; 101: 1462-74.
29. Shegokar R, Mueller RH. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010; 399: 129-39.
30. Sigfridsson K, Bjorkman JA, Skantze P, et al. Usefulness of a Nanoparticle Formulation to Investigate Some Hemodynamic Parameters of a Poorly Soluble Compound. J Pharm Sci 2011; 100: 2194-202.
31. Rabinow B, Kipp J, Papadopoulos P, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007; 339: 251-60.
32. Du SZ, Zhu L, Du B, et al. Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension. Drug Dev Ind Pharm 2012; 38: 431-8.
33. Wang YL, Li XM, Wang LY, et al. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomedicine 2011; 6: 1497-507.
34. Gao L, Zhang DR, Chen MH, et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 2008; 355: 321-7.
35. Chiang PC, Wahlstrom JL, Selbo JG, et al. 1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats. J Exp Nanosci 2007; 2: 239-50.
36. Van Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a longacting injectable antiretroviral formulation. Antimicrob Agents Ch 2010; 54: 2042-50.
37. Chiang PC, Ran Y, Chou KJ, Cui Y, Wong H. Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: Preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery. Nanoscale Res Lett 2011; 6: 413-21.
38. Mauludin R, Mueller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm 2009; 370: 202-9.
39. Sahoo NG, Kakran M, Shaal LA, et al. Preparation and Characterization of Quercetin Nanocrystals. J Pharm Sci 2011; 100: 2379-90.
40. Mishra PR, Al Shaal L, Muller RH, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm 2009; 371: 182-9.
41. Kobierski S, Ofori-Kwakye K, Muller RH, Keck CM. Resveratrol nanosuspensions for dermal application-production, characterization, and physical stability. Pharmazie 2009; 64: 741-7.
42. Al Shaal L, Mueller RH, Keck CM. Preserving hesperetin nanosuspensions for dermal application. Pharmazie 2010; 65: 86-92.
43. Chiang PC, Alsup JW, Lai YR, et al. Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery. Nanoscale Res Lett 2009; 4: 254-61.
44. Zhang JJ, Lv HX, Jiang K, Gao Y. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm 2011; 420: 180-8.
45. Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharmaceut Res 2002; 19: 189-94.
46. Kraft WK, Steiger B, Beussink D, et al. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol 2004; 44: 67-72.
47. Yang JZ, Young AL, Chiang PC, Thurston A, Pretzer DK. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci 2008; 97: 4869-78.
48. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in Ocular Drug Delivery: An Update Review. Curr Pharm Design 2009; 15: 2724-50.
49. Gupta S, Samanta MK, Raichur AM. Dual-Drug Delivery System Based on In Situ Gel-Forming Nanosuspension of Forskolin to Enhance Antiglaucoma Efficacy. Aaps Pharmscitech 2010; 11: 322-35.
50. Ventura MT, Viola M, Gaeta F, et al. Hypersensitivity reactions to ophthalmic products. Curr Pharm Design 2006; 12: 3401-10.
51. Gan L, Han S, Shen JQ, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm 2010; 396: 179-87.
52. Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 (R) nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002; 16: 53-61.
53. Ali HSM, York P, Ali AMA, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. J Control Release 2011; 149: 175-81.
54. Lele BS, Hoffman AS. Insoluble ionic complexes of polyacrylic acid with a cationic drug for use as a mucoadhesive, ophthalmic drug delivery system. J Biomat Sci-Polym E 2000; 11: 1319-31.
55. Du Toit LC, Pillay V, Choonara YE, Govender T, Carmichael T. Ocular drug delivery-a look towards nanobioadhesives. Expert Opin Drug Del 2011; 8: 71-94.
56. Barbu E, Verestiuc L, Iancu M, et al. Hybrid polymeric hydrogels for ocular drug delivery: nanoparticulate systems from copolymers of acrylic acid-functionalized chitosan and N-isopropylacrylamide or 2-hydroxyethyl methacrylate. Nanotechnology 2009; 20: 225108.
57. Diebold Y, Jarrin M, Saez V, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007; 28: 1553-64.
58. Mahmoud AA, El-Feky GS, Kamel R, Awad GEA. Chitosan/sulfobutylether-beta-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011; 413: 229-36.
59. Luo QH, Zhao JM, Zhang XR, Pan WS. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403: 185-91.
60. Scholz C, Wagner E. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J Control Release 2012; 161: 554-65.
61. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007; 24: 1-16.
62. Wang Y, Wang L, Liu Z, Zhang D, Zhang Q. In vivo evaluation of silybin nanosuspensions targeting liver. J Biomed Nanotechnol 2012; 8: 760-9.
63. Shegokar R, Jansch M, Singh KK, Mueller RH. In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy. Nanomed-Nanotechnol 2011; 7: 333-40.
64. Scholer N, Krause K, Kayser O, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Ch 2001; 45: 1771-9.
65. Shegokar R, Singh KK. HIV Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. Int J Pharm 2011; 421: 341-52.
66. Liu F, Park JY, Zhang Y, et al. Targeted Cancer Therapy With Novel High Drug-Loading Nanocrystals. J Pharm Sci 2010; 99: 3542-51.
67. Ganem-Quintanar A, Silva-Alvarez M, Alvarez-Roman R, et al. Design and evaluation of a self-adhesive naproxen-loaded film prepared from a nanoparticle dispersion. J Nanosci Nanotechnol 2006; 6: 3235-41.
68. Lou HY, Gao L, Wei XB, et al. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloid Surface B 2011; 87: 319-25.
69. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
70. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2: 3-14.
71. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64: 686-700.
72. Wang Q, Sun AY, Pardeike J, et al. Neuroprotective effects of a nanocrystal formulation of sPLA(2) inhibitor PX-18 in cerebral ischemia/reperfusion in gerbils. Brain Res 2009; 1285: 188-95.
73. Durazo SA, Kompella UB. Functionalized nanosystems for targeted mitochondrial delivery. Mitochondrion 2012; 12: 190-201.
74. Wenner CE. Targeting mitochondria as a therapeutic target in cancer. J Cell Physiol 2012; 227: 450-6.
75. Pierige F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev 2008; 60: 286-95.
76. Millan CG, Marinero MLS, Castaneda AZ, Lanao JM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release 2004; 95: 27-49.
77. Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release 2007; 118: 145-60.
78. Shen G, Wang Q, Zhang Q, et al. Tissue distribution of 2-methoxyestradiol nanosuspension in rats and its antitumor activity in C57BL/6 mice bearing lewis lung carcinoma. Drug Deliv 2012; 19: 327-33.
79. Zhang H, Hollis CP, Zhang Q, Li T. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm 2011; 415: 293-300.
80. Chavanpatil MD, Patil Y, Panyam J. Susceptibility of nanoparticleencapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 2006; 320: 150-6.
81. Yannakopoulou K. Novel multifunctional cyclodextrin-based nanocarriers for drug encapsulation and delivery as a strategy to overcome current therapeutic drawbacks Marie Curie Initial Training Networks (FP7-PEOPLE-ITN-2008). J Drug Deliv Sci Tec 2012; 22: 211-13.
82. Des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006; 116: 1-27.
83. Yao LP, Zhao XH, Li QY, et al. In vitro and in vivo evaluation of camptothecin nanosuspension: A novel formulation with high antitumor efficacy and low toxicity. Int J Pharm 2012; 423: 586-8.
84. Tevaarwerk AJ, Holen KD, Alberti DB, et al. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 2009; 15: 1460-5.
85. Harrison MR, Hahn NM, Pili R, et al. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs 2011; 29: 1465-74.
86. Zheng DD, Wang YC, Zhang DR, et al. In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett 2011; 307: 158-64.
87. Elamanchili P, Mceachern C, Burt H. Reversal of Multidrug Resistance by Methoxypolyethylene Glycol-block-Polycaprolactone Diblock Copolymers Through the Inhibition of PGlycoprotein Function. J Pharm Sci 2009; 98: 945-58.
88. Alakhova DY, Rapoport NY, Batrakova EV, et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancers. J Control Release 2010; 142: 89-100.
89. Shaik N, Giri N, Elmquist WF. Investigation of the Micellar Effect of Pluronic P85 on P-glycoprotein Inhibition: Cell Accumulation and Equilibrium Dialysis Studies. J Pharm Sci 2009; 98: 4170-90.
90. Gao Y, Li ZG, Sun M, et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm 2010; 36: 1225-34.
91. Qi XL, Zhang DR, Xu X, et al. Oridonin nanosuspension was more effective than free oridonin on G(2)/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int J Nanomedicine 2012; 7: 1793-804.
92. Lou HY, Zhang XM, Gao L, et al. In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm 2009; 379: 181-6.
93. Wang P, Zheng GJ, Wang YP, et al. Highly practical and costefficient synthesis of telmisartan: an antihypertensive drug. Tetrahedron 2012; 68: 2509-12.
94. Espina IM, Varon J. Clevidipine: a state-of-the-art antihypertensive drug under the scope. Expert Opin Pharmaco 2012; 13: 387-93.
95. Yu ZG, Xu FY, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000; 87: 992-8.
96. Wahlstrom JL, Chiang PC, Ghosh S, et al. Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Res Lett 2007; 2: 291-6.
97. Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm 2011; 79: 635-51.
98. Gad S, Tajber L, Corrigan OI, Healy AM. Preparation and characterisation of novel spray-dried nano-structured paraaminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state. J Pharm Pharmacol 2012; 64: 1264-74.
99. Beck-Broichsitter M, Merkel OM, Kissel T. Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release 2012; 161: 214-24.
100. Chiang PC, Hu Y, Blom JD, Thompson DC. Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations. Nanoscale Res Lett 2010; 5: 1010-9.
101. Hernandez-Trejo N, Kayser O, Steckel H, Muller RH. Characterization of nebulized buparvaquone nanosuspensions-effect of nebulization technology. J Drug Target 2005; 13: 499-507.
102. Du Y, Liu P, Zhu H, et al. A sensitive analysis method for 7 diterpenoids in rat plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to pharmacokinetic study of Isodon serra extract. J Chromatogr A 2011; 1218: 7771-80.
103. Noudeh GD, Khazaeli P, Behravan E, et al. Evaluating the toxicity of permeability enhanchers of polyethylene glycol brij ethers surfactants group on cellular membranes and some of their physicochemical properties. Afr J Biotechnol 2011; 10: 9931-38.
104. Ramadan LA, Shouman SA, Sayed-Ahmed MM, El-Habit OH. Modulation of radiation-induced organs toxicity by cremophor-el in experimental animals. Pharmacol Res 2001; 43: 185-91.
105. Zhang S, Ji G, Liu J. Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. J Nutr Biochem 2006; 17: 485-91.
106. Ruddick JA. Toxicology, metabolism, and biochemistry of 1,2-propanediol. Toxicol Appl Pharmacol 1972; 21: 102-11.
107. Budden R, Kuhl UG, Bahlsen J. Experiments on the toxic, sedative and muscle relaxant potency of various drug solvents in mice. Pharmacol Ther B 1979; 5: 467-74.
108. Morshed KM, Nagpaul JP, Majumdar S, Amma MK. Kinetics of propylene glycol elimination and metabolism in rat. Biochem Med Metab Biol 1988; 39: 90-7.
109. Kumar MP, Rao YM, Apte S. Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Curr Nanosci 2007; 3: 191-4.
110. Quan P, Shi K, Piao H, et al. A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. Int J Pharm 2012; 430: 366-71.
111. Mueller RH, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN (R) versus drug nanocrystals. Int J Pharm 2006; 317: 82-9.
112. Mease K, Sane R, Podila L, Taub ME. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci 2012; 101: 1888-97.
113. Volpe DA. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med Chem 2011; 3: 2063-77.
114. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the humancolon carcinoma cell-line (caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96: 736-49.
115. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliver Rev 2001; 46: 27-43.
116. Wilson G. Cell culture techniques for the study of drug transport. Eur J Drug Metab Pharmacokinet 1990; 15: 159-63.
117. Zhao S, Dai W, He B, et al. Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. J Control Release 2012; 158: 413-23.
118. Fazlollahi F, Angelow S, Yacobi NR, et al. Polystyrene nanoparticle trafficking across MDCK-II. Nanomedicine 2011; 7: 588-94.
119. Van Eerdenbrugh B, Froyen L, Martens JA, et al. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm 2007; 338: 198-206.
120. Beck RC, Pohlmann AR, Hoffmeister C, et al. Dexamethasoneloaded nanoparticle-coated microparticles: correlation between in vitro drug release and drug transport across Caco-2 cell monolayers. Eur J Pharm Biopharm 2007; 67: 18-30.
121. Song CK, Balakrishnan P, Shim CK, Chung SJ, Kim DD. Enhanced in vitro cellular uptake of P-gp substrate by poloxamermodified liposomes (PMLs) in MDR cancer cells. J Microencapsul 2011; 28: 575-81.
122. Shaik N, Pan G, Elmquist WF. Interactions of Pluronic Block Copolymers on P-gp Efflux Activity: Experience With HIV-1 Protease Inhibitors. J Pharm Sci 2008; 97: 5421-33.
123. Evers R, Kool M, Smith AJ, et al. Inhibitory effect of the reversal agents V-104, GF120918 and pluronic L61 on MDR1 Pgp-, MRP1-and MRP2-mediated transport. Brit J Cancer 2000; 83: 366-74.
124. Collnot EM, Baldes C, Schaefer UF, et al. Vitamin E TPGS Pglycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm 2010; 7: 642-51.
125. Collnot EM, Baldes C, Wempe MF, et al. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007; 4: 465-74.
126. Simon S, Schubert R. Inhibitory effect of phospholipids on Pglycoprotein: Cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements. Bba-Mol Cell Biol L 2012; 1821: 1211-23.
127. Spernath A, Aserin A, Ziserman L, Danino D, Garti N. Phosphatidylcholine embedded microemulsions: physical properties and improved Caco-2 cell permeability. J Control Release 2007; 119: 279-90.
128. Navarro C, Gonzalez-Alvarez I, Gonzalez-Alvarez M, et al. Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model. Eur J Pharm Sci 2011; 42: 290-9.
129. Sadeghi AM, Dorkoosh FA, Avadi MR, et al. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur J Pharm Biopharm 2008; 70: 270-8.
130. Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002; 237: 151-61.
131. Pabla D, Akhlaghi F, Zia H. Intestinal permeability enhancement of levothyroxine sodium by straight chain fatty acids studied in MDCK epithelial cell line. Eur J Pharm Sci 2010; 40: 466-72.
132. Sun W, Tian W, Zhang YY, et al. Effect of novel stabilizerscationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. Nanomed-Nanotechnol 2012; 8: 460-7.
133. Shegokar R, Singh KK. Nevirapine nanosuspensions for HIV reservoir targeting. Pharmazie 2011; 66: 408-15.
134. Moghimi SM, Muir IS, Illum L, Davis SS, Kolbbachofen V. Coating Particles with a Block-Copolymer (Poloxamine-908) Suppresses Opsonization but Permits the Activity of Dysopsonins in the Serum. Biochim Biophys Acta 1993; 1179: 157-65.
135. Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. Int J Pharm 2011; 421: 341-52.
136. Li WJ, Das S, Ng KY, Heng PWS. Formulation, Biological and Pharmacokinetic Studies of Sucrose Ester-Stabilized Nanosuspensions of Oleanolic Acid. Pharma Res 2011; 28: 2020-33.
137. Quan P, Xia D, Piao H, et al. Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation. AAPS PharmSciTech 2011; 12: 1136-43.
138. Xia D, Quan P, Piao H, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci 2010; 40: 325-34.
139. Langguth P, Hanafy A, Frenzel D, et al. Nanosuspension formulations for low-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm 2005; 31: 319-29.
140. Onoue S, Takahashi H, Kawabata Y, et al. Formulation Design and Photochemical Studies on Nanocrystal Solid Dispersion of Curcumin With Improved Oral Bioavailability. J Pharm Sci 2010; 99: 1871-81.
141. Liu Y, Zhang D, Duan C, et al. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery. J Microencapsul 2012; 29: 194-203.